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ABSTRACT:
Daphnetin has been developed as an oral medicine for treatment
of coagulation disorders and rheumatoid arthritis in China, but
its in vitro metabolism remains unknown. In the present study,
the UDP-glucuronosyltransferase (UGT) conjugation pathways
of daphnetin were characterized. Two metabolites, 7-O-
monoglucuronide daphnetin (M-1) and 8-O-monoglucuronide
daphnetin (M-2), were identified by liquid chromatography/mass
spectrometry and NMR when daphnetin was incubated, respec-
tively, with liver microsomes from human (HLM), rat (RLM), and
minipig (PLM) and human intestinal microsomes (HIM) in the pres-
ence of UDP-glucuronic acid. Screening assays with 12 human
recombinant UGTs demonstrated that the formations of M-1 and
M-2 were almost exclusively catalyzed by UGT1A9 and UGT1A6,
whereas M-1 was formed to a minor extent by UGT1A3, 1A4, 1A7,
1A8, and 1A10 at a high substrate concentration. Kinetics studies,
chemical inhibition, and correlation analysis were used to demon-
strate that human UGT1A9 and UGT1A6 were major isoforms in-
volved in the daphnetin glucuronidations in HLM and HIM. By in
vitro-in vivo extrapolation of the kinetic data measured in HLM, the
hepatic clearance and the corresponding hepatic extraction ratio
were estimated to be 19.3 ml/min/kg b.wt. and 0.93, respectively,
suggesting that human clearance of daphnetin via the glucuronida-
tion is extensive. Chemical inhibition of daphnetin glucuronidation
in HLM, RLM, and PLM showed large species differences although
the metabolites were formed similarly among the species. In con-
clusion, the UGT conjugation pathways of daphnetin were fully
elucidated and its C-8 phenol group was more selectively cata-
lyzed by UGTs than by the C-7 phenol.
Benzo--pyrone skeleton-containing coumarins are widely distrib-
uted in the plant kingdom and have a general application in food,
drug, and cosmetic products (Egan et al., 1990). As one of coumarin
derivatives, daphnetin (7,8-dihydroxycoumarin) has exhibited broad
biological activities, such as anti-inflammatory (Fylaktakidou et al.,
2004), antioxidant (Fylaktakidou et al., 2004), antimicrobial (Cottiglia
et al., 2001), and antimalarial (Huang et al., 2006) effects as well as
protein kinase inhibitory activities (Yang et al., 1999). Clinically,
daphnetin not only has been developed as an oral medicine for
treatment of coagulation disorders and rheumatoid arthritis in China
since the 1980s (http://app1.sfda.gov.cn/datasearch/face3/base.jsp)
but also has been used as a folk medicine to treat lumbago and reduce
fever in Turkey (Yesilada et al., 2001). Moreover, recent studies
demonstrated that daphnetin can act as a potent antiproliferative and
differentiation-inducing agent in human renal cell carcinoma (Finn et
al., 2004).
The pharmacokinetic study of daphnetin in rats after intravenous
administration shows that the elimination of daphnetin is rapid with a
t1/2 of approximately 15 min and poor bioavailability; however, the
mechanisms responsible for the pharmacokinetic properties are un-
clear (Qu et al., 1983). Structurally, daphnetin contains a catechol
group on its basic skeleton, which could be susceptible to metabolism
by phase II enzymes, such as UDP-glucuronosyltransferases (UGTs),
sulfotransferases, and catechol-O-methyltransferases (Antonio et al.,
2002, 2003). Many glucuronidation derivatives of catechol-containing
drugs have been detected both in vitro and in vivo, e.g., L-3,4-
dihydroxyphenylalanine, a therapeutic drug for Parkinson’s disease
(Antonio et al., 2002, 2003); protocatechuic aldehyde, a antiasthmatic
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agent (Liu et al., 2008); and 2-((2-(1H-imidazol-1-yl)-6-methylpyri-
midin-4-yl)(3-((benzo-[d][1,3]dioxol-5-ylmethyl)(methyl)amino)pro-
pyl)amino)acetamide (PH-302), an inhibitor of nitric oxide synthase
(Loureiro et al., 2006). On the other hand, it was noted in previous
studies that 7-hydroxycoumarin and 4-methylumbelliferone, the struc-
tural analogs of daphnetin, are substrates for the UGTs with high
affinity (Uchaipichat et al., 2004; Wang et al., 2006). Therefore, it is
necessary to understand the role of glucuronidation in the metabolic
elimination of daphnetin because the glucuronidation of most benzo-
-pyrones has been demonstrated as a primary route of clearance
(Tukey and Strassburg, 2000).
Glucuronidation, the major phase II conjugation reaction, accounts
for 35% of all phase II drug metabolites (Kiang et al., 2005).
Nineteen human UGT isoforms have been identified, and these UGTs
have been classified into two families (UGT1 and UGT2) based on
their sequence identity (Tukey and Strassburg, 2000; Mackenzie et al.,
2005). Many UGTs have had broad and overlapping substrate spec-
ificities, although the specificity of UGT isoforms to certain substrates
is known (e.g., UGT1A1 for bilirubin, UGT1A4 for trifluoperazine,
UGT1A6 for serotonin, UGT1A9 for propofol, and UGT2B7 for
3-azido-3-deoxythymidine) (Court, 2005; Miners et al., 2006). In
addition, human UGTs are tissue-specific because of their differences
in expression. For example, UGT1A7, 1A8, 2A1, and 1A10 are
expressed mainly in extrahepatic tissues, although liver is generally
recognized as the major site of glucuronidation (Fisher et al., 2001).
It is notable that highly interindividual variability and the differential
UGT expression within different segments of the gut have been also
reported (Strassburg et al., 1998). Identification of the human UGT
isoform(s) responsible for drug glucuronidation is the pivotal infor-
mation to understand the potential of clinical drug-drug interactions
for drugs or drug candidates as the victims when they were coadmin-
istered with an inhibitor of the target UGT(s). Furthermore, the in vivo
clearance prediction from in vitro enzyme kinetic parameters can be
used to evaluate the quantitative contribution of the UGT(s) to total
clearance of a drug.
To date, information on the metabolism of daphnetin still remains
unclear. The purposes of the present study are 1) to characterize the in
vitro metabolites of daphnetin, 2) to identify the human UGT iso-
form(s) responsible for the formation of the metabolites, 3) to deter-
mine the kinetics of daphnetin glucuronides in microsomes from
human liver (HLM), human intestine (HIM), rat liver (RLM), and
minipig liver (PLM) and recombinant UGTs, respectively, and 4) to
compare the species differences by inhibition analyses.
Materials and Methods
Chemicals and Reagents. Daphnetin (97%), alamethicin, Brij 58, mag-
nesium chloride, D-saccharic acid 1,4-lactone, -glucuronidase (EC 3.2.1.31),
UDP-glucuronic acid trisodium salt (UDPGA), serotonin, propofol, mefenamic
acid, and phenylbutazone were purchased from Sigma-Aldrich (St. Louis,
MO). Microcon1 YM-30 centrifugal filter devices were obtained from Milli-
pore Corporation (Billerica, MA). HLM, RLM, and PLM were prepared
according to the methods described by Guengerich (1989) and previous reports
(Zhang et al., 2008). Protein concentration was determined by using bovine
serum albumin as the standard (Lowry et al., 1951). Pooled HIM containing
equal amounts of microsomes were prepared from both the duodenum and
jejunum sections of each of the five donors (one female and four males of
white and African-American race, with ages ranging from 16 to 64 years) and
a panel of recombinant human UGT Supersomes expressed in baculovirus-
infected insect cells was purchased from BD Gentest (Woburn, MA). The
glucuronidation activities of Supersomes using different substrates (estradiol
for UGT 1A1 and UGT1A3, trifluoperazine for UGT1A4, eugenol for
UGT2B17, and 4-methylumbelliferone for UGT1A6, 1A7, 1A8, 1A9, 1A10,
2B4, 2B7, and 2B15) were substantiated by the supplier, with the values of
1000, 250, 1300, 2200, 6900, 12,000, 630, 8700, 86, 330, 1300, and 2100
pmol/min/mg, respectively. Millipore water (Millipore Corporation) and
HPLC-grade methanol and acetonitrile (Tedia Company, Inc., Fairfield, OH)
were used throughout; other reagents were of HPLC grade or of the highest
grade commercially available.
Identification of Daphnetin Glucuronidation. The incubation mixture
(200 l) contained HLM (0.5 mg of protein/ml), 5 mM UDPGA, 5 mM
MgCl2, 25 g/ml alamethicin, 10 mM D-saccharic acid 1,4-lactone, 200 M
daphnetin, and Tris-HCl buffer (pH 7.4). After 10 min of incubation at 37°C,
the reaction was terminated by the addition of 0.1 ml of methanol containing
0.3 g of internal standard (7-hydroxycoumarin), followed by centrifugation at
20,000g for 10 min to obtain the supernatant for ultra-fast liquid chromatog-
raphy (UFLC) spectrometry analysis. Control incubations without UDPGA or
without substrate or without microsomes were performed to ensure that the
metabolites produced were microsome- and UDPGA-dependent. An LCMS-
2010EV mass spectrometer system (Shimadzu, Kyoto, Japan) with an electro-
spray ionization (ESI) interface was used to identify daphnetin and its metab-
olites (M-1 and M-2) operating in both negative and positive ion modes from
m/z 100 to 1000. The detector voltage was set at 1.50 and 1.55 kV for
positive and negative ion detection, respectively. The curved desolvation line
temperature and the block heater temperature were both set at 250°C. Other
MS detection conditions were set as follows: voltage, 4 kV; interface voltage,
40 V; nebulizing gas (N2) flow, tuned to be 1.5 l/min; and drying gas (N2)
pressure, 0.06 MPa. Data processing was performed using UFLC-MS Solution
version 3.41 software (Shimadzu, Kyoto, Japan).
To confirm that these two metabolites are glucuronide compounds, 200 l
of glucuronidation incubation mixture (see above, but without D-saccharic acid
1,4-lactone) was incorporated into an equal volume of 0.15 M acetate buffer
(pH 5.0) containing 1800 Fishman units of -glucuronidase. After a 2-h
incubation at 37°C, the hydrolysis reaction was terminated by addition of
0.1 ml of cold methanol, followed by centrifugation at 20,000g for 10 min,
and then 10 l of supernatant was injected for UFLC-DAD-ESI-MS
analysis. Control incubations without -glucuronidase were performed
simultaneously.
Biosynthesis Metabolite and NMR Spectrometry. The glucuronidation
metabolites (M-1 and M-2) of daphnetin were biosynthesized and purified for
structure elucidation and quantitative analysis. Enzymatic biosynthesis of M-1
and M-2 was conducted using RLM, because they resemble HLM in daphnetin
metabolism. In brief, 600 M daphnetin was incubated with RLM (0.5 mg of
protein/ml), 0.1 M Tris-HCl, pH 7.4, 10 mM MgCl2, Brij 58 (0.5 mg/mg
protein), 10 mM D-saccharic acid 1,4-lactone, and 5 mM UDPGA in 100-ml
final incubations for 2 h at 37°C. The stock solution of daphnetin (60 mM) was
prepared in methanol. The concentration of organic solvent in the final incu-
bation was 1%. The reaction was terminated by transferring the vessel to an ice
bath and cooling for 20 min. After removal of protein by centrifugation at
20,000g for 15 min at 4°C, the combined supernatants were loaded on a
solid-phase extraction cartridge (C18, 1000 mg; Agela Technologies Inc.,
Newark, DE), which was preconditioned by sequential washing with 5 ml of
methanol and 5 ml of water containing 0.2% formic acid. After loading of the
incubation material, the cartridge was washed with 15 ml of water containing
0.2% formic acid. Then, the trapped compounds were eluted with 5 ml of
methanol and blown dry with nitrogen gas at 20°C. Finally, the residual was
redissolved in 1 ml of methanol and separated by HPLC (Shimadzu) equipped
with an SCL-10A system controller, two LC-10AT pumps, an SIL-10A auto-
injector, an SPD-10AVP UV detector, and a Shim-pack C18 column (4.6 
150 mm, 5 m; Shimadzu). The mobile phase consisted of CH3CN (A) and
0.2% (v/v) formic acid (B) with a linear gradient from initially 5 to 80% A over
15 min. The flow rate was 1.4 ml/min. The purity was greater than 99% for
both metabolites by using UFLC-diode array detection.
The structures of metabolites M-1 and M-2 were determined by spectral
methods including two-dimensional NMR such as heteronuclear single quan-
tum correlation, heteronuclear multiple-bond correlation spectroscopy, and
nuclear Overhauser effect spectroscopy. All experiments were recorded on an
AV-600 system (Bruker, Newark, Germany). The purified metabolites of M-1
(2.6 mg) and M-2 (2.3 mg) were stored at 20°C before dissolving in dimethyl
sulfoxide-d6 (Euriso-Top, Saint-Aubin, France) for NMR analysis. Chemical
shifts are given on a  scale and referenced to tetramethylsilane at 0 ppm for
1H NMR (600 MHz) and 13C NMR (150 MHz).
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Assay with Recombinant UGTs. Daphnetin glucuronidation was measured
in reaction mixtures containing recombinant human UGT1A1, 1A3, 1A4, 1A6,
1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B15, and 2B17. The incubations were
performed as shown above for the HLM study. Three substrate concentrations
(10, 100, and 600 M) were used in this study: 600 and 100 M were the
approximate concentrations at Vmax and Km values for HLM, respectively;10
M was used to evaluate the catalytic activity of the UGT isoform(s) with high
affinity for daphnetin glucuronidation. All assays were conducted at 37°C for
60 min with the final protein concentration of 0.5 mg of protein/ml. UFLC with
diode array detection was used to monitor possible metabolites.
Chemical Inhibition Studies. Daphnetin glucuronidation in pooled HLM,
HIM, UGT1A6, and UGT1A9 were measured in the absence or presence of
inhibitor (phenylbutazone or mefenamic acid). Phenylbutazone is a potent
inhibitor for UGT1As (Uchaipichat et al., 2006) and mefenamic acid is a
potent inhibitor for UGT1A9 (Tachibana et al., 2005). Daphnetin (100 M)
was incubated in the absence or presence of either phenylbutazone (10–500
M) or mefenamic acid (1–50 M). All incubations were performed for 10
min using a concentration of 0.1 mg of protein/ml. The IC50, representing the
concentration that inhibits 50% of control activity, was determined by nonlin-
ear curve fitting with Origin (OriginLab Corporation, Northampton, MA), as
described previously (Zhang et al., 2009). For comparison of the inhibitory
effects of phenylbutazone and mefenamic acid among different species, ex-
periments with several concentrations of phenylbutazone (50 and 500 M) and
mefenamic acid (10 and 100 M) in pooled liver microsomes from humans,
rats, and minipigs were conducted to investigate their inhibitory effects on
daphnetin glucuronidation.
Correlation Analysis in HLM. Linear regression analysis was used to
assess the correlation between the glucuronidation activity toward daphnetin
and serotonin or propofol in microsomes from 14 individual human livers.
The activities of UGT1A6-catalyzed serotonin glucuronidation and UGT1A9-
catalyzed propofol glucuronidation were 1.27 to 3.05 and 0.25 to 2.20 nmol/
min/mg protein, respectively. The daphnetin and HLM concentrations were
100 M and 0.1 mg of protein/ml, respectively. The reaction mixture was
incubated for 10 min at 37°C. The glucuronidation activities of serotonin and
propofol were provided by the manufacturer as typical reference activities for
UGT1A6 and UGT1A9, respectively. P  0.05 was considered statistically
significant.
Kinetic Study. The formation rates of daphnetin metabolites were linear
over 30 min of incubation and 0.05 to 0.3 mg of microsomal protein. To ensure
that less than 10% of substrate was metabolized in all incubations, the kinetic
determinations were performed using a microsomal protein concentration of
0.1 mg/ml (HLM, HIM, PLM, PLM, or Supersomes) with a 10-min incubation.
For estimating kinetic parameters, daphnetin (5–600 M) was incubated with
pooled microsomes from different sources (HLM, HIM, PLM, or RLM). For
recombinant human UGT1A9 and UGT1A6, daphnetin (5–400 M) was
incubated with UGT1A9 and UGT1A6 for kinetic analysis. Kinetic constants
for daphnetin glucuronidation by HLM, HIM, UGT1A9, or UGT1A6 were
obtained by fitting with the Michaelis-Menten equation using Origin. The
Michaelis-Menten equation is v  (Vmax  [S])/(Km  [S]), where v is the rate
of reaction, Vmax is the maximum velocity, Km is the Michaelis constant
(substrate concentration at 0.5 Vmax), and [S] is the substrate concentration.
Results are expressed as mean  computer-calculated S.E. of the estimate.
Quantitative Analysis. Daphnetin glucuronides were separated and quan-
tified by UFLC using a Shimadzu Prominence UFLC system, which was
equipped with a CBM-20A communications bus module, an SIL-20ACHT
autosampler, two LC-20AD pumps, a DGU-20A3 vacuum degasser, and a
CTO-20AC column oven, as well as a DAD. A Shim-pack XR-ODS column
(100 mm  2.0 mm, 2.2 m; Shimadzu) was kept at 40°C. Elution was
performed with the following gradient program with solvent A (CH3CN) and
solvent B (0.2% formic acid): 0 to 2 min, 95 to 83% B; 2 to 7 min, 85 to 76%
B; 7 to 9.5 min, 10% B; and 9.5 to 14.5 min, 95% B. The flow rate was 0.3
ml/min, and the detection wavelength was set at 320 nm. The biosynthesized
glucuronidation metabolites M-1 and M-2 were dissolved in methanol and
used as the calibration standards. The calibration curves were generated by
peak area ratios (calibration standard/internal standard) over the concentration
range of 0.5 to 30 M. The standard curves of the two metabolites were linear
over this concentration range, with r2 values 0.99. The limits of detection and
quantification were determined at signal/noise ratios of 3 and 10, respectively.
The accuracy and precision of the back-calculated values for each concentra-
tion were less than 15%.
Prediction of Tissue Clearances from In Vitro Data. The in vivo intrinsic
clearances (CLint) of daphnetin glucuronidation in liver and intestine were











where Vmax is the maximum velocity, Km is the Michaelis constant, and fu,m is
the free fraction of daphnetin in the microsomes. The scaling factors for human
liver (40 mg/g and 21.4 g/kg b.wt.) and intestine (3 mg/g and 30 g/kg b.wt.)
used in these calculations were obtained from Cubitt et al. (2009) and Soars et






  1 (2)
where Cmic is the microsomal protein concentration used in the incubation,
the value of which is 0.1 mg/ml for both HIM and HLM, and logP is the
log of the octanol buffer (pH 7.4) partition (P) coefficient of the daphnetin,
the value of which is 1.2 (http://pubchem.ncbi.nlm.nih.gov/summary/
summary.cgi?sid5991). Therefore, the bound fraction of daphnetin to
microsomal protein can be negligible in this study.
For evaluation of the magnitude of UGT conjugation pathways to the
elimination of daphnetin, the hepatic clearance (CLH) was predicted from the
resulting estimated in vivo hepatic intrinsic clearance (CLint, liver) using eq. 3,
based on the well stirred model (Miner et., al 2006):
CLH 
QH  fu,b  CLint, liver
QH  fu,b  CLint, liver
(3)
where fu,b is the fraction unbound of daphnetin in blood, QH is hepatic blood
flow, and QH values of 20.7 ml/min/kg wt. (Cubitt et al., 2009) were used.
Fractions unbound of daphnetin in blood and plasma (fu,p) were considered
equivalent for extrapolation purposes, although it is acknowledged that some
difference may occur. fu,p was obtained from the separate experiments using
the ultrafiltration method (Taylor and Harker, 2006) at two concentrations
(17.8 and 178 ng/ml) of daphnetin.
Results
Identification of Daphnetin Metabolites. Two new peaks were
eluted at 4.0 (M-1) and 4.5 min (M-2), respectively, by UFLC when
daphnetin (200 M) was incubated with HLM, HIM (data not shown),
RLM, or PLM (0.1 mg/ml) in the presence of UDPGA (Fig. 1). The
FIG. 1. Representative UFLC-DAD profile of daphnetin and its metabolites; 0.1
mg/ml PLM (1), RLM (2), or HLM (3) was incubated with daphnetin (200 M) at
37°C for 30 min with UDPGA (5 mM) as described under Materials and Methods.
Metabolites M-1 and M-2, daphnetin, and internal standard (7-hydroxycoumarin)
were eluted at 4.0, 4.5, 5.0, and 6.3 min, respectively.
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peaks were not detected in the control samples in the absence of
UDPGA, daphnetin, or microsomes (data not shown). The negative-
ion mode was adopted for chemical identification because it is more
sensitive than the positive-ion mode for daphnetin and its metabolites.
Mass spectra were dominated by [M  H]. M-1 and M-2 were
identified by UFLC-ESI-MS to show identical product ions at m/z 353
in negative-ion mode with characteristic m/z 176, corresponding to the
glucuronide. In addition, these two metabolites were hydrolyzed by
-glucuronidase to the parent (daphnetin), indicating that M-1 and
M-2 are the monoglucuronide metabolites. The two metabolites were
further purified and characterized for structural elucidation by 1H
NMR, 13C NMR, heteronuclear single quantum correlation, and het-
eronuclear multiple-bond correlation spectroscopy spectral technol-
ogy (Table 1). Compared with that of daphnetin, the 13C NMR
spectrum of metabolite M-1 showed that C-7 of M-1 shifted upfield to
 147.8 ( 1.9) because of the glycosidation shift of phenolic
compounds, whereas C-6 and C-8 shifted downfield to 114.5 (
1.9) and 134.1 ( 1.8), respectively (Table 1). All of this
evidence indicated that the glucuronosyl substitution should be at the
C-7 phenolic group. Likewise, M-2 was identified to be the 8-O-
monoglucuronide daphnetin by comparing with the 13C NMR spec-
trum of daphnetin and regulation of the glycosidation shift. Moreover,
all of the 1H and 13C NMR spectral data of metabolites M-1 and M-2
were assigned by the two-dimensional NMR spectra (data not shown).
Assay with Recombinant Human UGTs. With the substrate con-
centrations of 10 or 100 M, UGT1A6 and UGT1A9 were the only
isoforms involved in the glucuronidation of daphnetin. At the high
substrate concentration (600 M), UGT1A6 and UGT1A9 were still
the major isoforms involved in daphnetin glucuronidation, although
trace amounts of M-1 were formed by UGT1A3, 1A4, 1A7, 1A8, and
1A10 (20 pmol/min/mg protein) (Fig. 2).
Chemical Inhibition. The inhibitory effects of phenylbutazone and
mefenamic acid on daphnetin glucuronidation in pooled HLM, HIM,
UGT1A6, and UGT1A9 were evaluated. As shown in Table 2, phe-
nylbutazone inhibited potently the UGT activity for the formation of
the metabolites in HLM, HIM, UGT1A6, and UGT1A9. Mefenamic
acid appeared generally to be more potent in inhibition than phenyl-
butazone except for UGT1A6. Similar IC50 values of phenylbutazone
for HLM, HIM, UGT1A6, and UGT1A9 were measured. However,
mefenamic acid showed differential inhibitory effects on the enzyme
activity, whereas the inhibition of UGT1A6 (IC50  50 M) was
poorer than that observed for other enzyme preparations. As shown in
Fig. 3, the inhibitory profiles of phenylbutazone and mefenamic acid
on daphnetin glucuronidation in HLM, RLM, and PLM are illustrated
to show the species difference. The inhibition rank order of daphnetin
glucuronidation among the species was HLM  PLM  RLM for
phenylbutazone and HLM  RLM  PLM for mefenamic acid,
respectively.
Correlation Analysis. The velocities for daphnetin glucuronida-
tion in liver microsomes from 14 human donors were obtained and
range from 1.2 to 10.6 nmol/min/mg protein for M-1 and from 1.3 to
7.8 nmol/min/mg protein for M-2, respectively. The means  S.D. for
rate of the metabolite formation of M-1 and M-2 were 6.0  3.3 and
4.8  2.8 nmol/min/mg protein, with a coefficient of variation (CV)
of 57.9% for M-1 and 59.3% for M-2, respectively. Correlation
analyses were performed between the daphnetin glucuronosyltrans-
ferase activities and serotonin (UGT1A6) or propofol (UGT1A9)
glucuronosyltransferase activities in 14 human liver microsomes. As
shown in Fig. 4, the daphnetin glucuronosyltransferase activities were
significantly correlated with the propofol glucuronosyltransferase ac-
FIG. 2. The formation of two metabolites, M-1 (A) and M-2 (B), catalyzed by
various recombinant human UGTs. Daphnetin (10, 100, and 600 M) was incubated
with various recombinant human UGTs (0.5 mg/ml) at 37°C for 60 min. Data
represent the mean of duplicate incubations.
TABLE 1
Proton and carbon NMR chemical shift assignments for daphnetin and its metabolites
Position
Daphnetin M-1 M-2
 1H Mult (J in Hz)  13C  1H Mult (J in Hz)  13C  1H Mult (J in Hz)  13C
2 160.4 160.0 159.9
3 6.19 t (9.6) 111.2 7.09 d (8.4) 112.0 6.85 d (8.4) 113.6
4 7.90 d (9.0) 143.7 7.95 d (9.6) 142.8 7.93 d (9.6) 144.7
5 7.01 d (8.4) 118.8 7.13 d (9.0) 118.2 7.30 d (8.4) 124.3
6 6.80 t (7.8) 112.5 6.32 d (9.6) 114.5 6.22 d (9.6) 111.4
7 9.33 brs 149.7 147.8 154.0
8 10.01 brs 132.1 134.1 130.9
9 145.1 144.6 147.8
10 112.1 113.5 113.7
1 5.04 d (7.8) 101.2 5.02 d (7.2) 103.8
2 3.38 (1H, m) 72.9 3.42 (1H, m) 73.4
3 3.34 (1H, m) 75.2 3.28 (1H, m) 75.7
4 3.41 (1H, m) 71.4 3.48 (1H, m) 71.6
5 3.90 (1H, d, J  9.6 Hz) 75.3 3.61 (1H, d, J  9.0 Hz) 76.2
6 170.1 170.4
brs, broad singlet; d, doublet; t, triple; m, multiplet.
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tivities (r  0.91, P  0.001 for M-1; r  0.94, P  0.001 for M-2)
and serotonin glucuronosyltransferase activities (r  0.64, P  0.011
for M-1; r  0.69, P  0.006 for M-2).
Kinetic Characterization. The kinetic parameters of M-1 and M-2
production in HLM, HIM, RLM, PLM, and the potent UGT isoforms
were determined and are shown in Table 3. It was unrealistic to
evaluate the kinetic parameters in UGT1A3, 1A4, 1A7, 1A8, and
1A10, because the metabolite (M-1) formation rate was close to the
limits of quantification. The ranges of substrate concentration for the
kinetic analyses in liver and intestine microsomal assays were 5 to
600 and 5 to 400 M in UGT1A9 and UGT1A6, respectively. In
the concentration ranges tested, daphnetin glucuronidation exhib-
ited Michaelis-Menten kinetic characteristics, as evidenced by a
linear Eadie-Hofstee plot (Fig. 5). The in vitro total intrinsic
clearances (the sum of M-1 and M-2, calculated as Vmax/Km) of the
glucuronidation of daphnetin in human liver and intestinal micro-
somes were 402 and 108 l/min/mg protein, respectively. By
scaling-up, the in vivo intrinsic clearances in liver and intestine
were estimated to be 344 and 9.7 ml/min/kg b.wt., respectively.
Based on the detected fu, p (0.8), the in vivo hepatic intrinsic
clearance was further extrapolated to the hepatic clearance with the
value of 19.3 ml/min/kg b.wt. using the well stirred model equation
(see Materials and Methods). The hepatic extraction ratio, calcu-
lated from the ratio of the predicted hepatic clearance and the
hepatic blood flow, was 0.93. The intrinsic clearance values (Vmax/
Km) for the two metabolites among the species were M-1  M-2 in
HLM, M-2  M-1 in PLM, and M-2  M-1 in RLM. Intrinsic
clearance values (M-1 and M-2) in species were PLM  RLM 
HLM.
Discussion
Most of the hydroxycoumarin derivatives sharing their benzo--
pyrone skeleton are good substrates of human UGTs (Tukey and
Strassburg, 2000). For example, 4-methylumbelliferone has been
widely used as a nonselective probe for evaluation of glucuronidation
activities (UGT1A1, 1A3, 1A6, 1A7, 1A8, 1A9, 1A10, 2B7, 2B15,
and 2B17) because of its high affinity for UGTs and turnover for the
formation of the metabolite (Uchaipichat et al., 2004). With respect to
the catechol compounds, UGT1A6, UGT1A9, and UGT2B7 can po-
tentially be involved in their glucuronidation (Antonio et al., 2003;
Loureiro et al., 2006). Daphnetin is a hydroxycoumarin derivative as
well as a catechol-containing compound. In the present study,
UGT1A9 and UGT1A6 were the most capable of catalyzing the
glucuronidation of daphnetin at three substrate concentrations, but a
trace amount of daphnetin 7-O-glucuronide could be formed by
UGT1A3, 1A4, 1A7, 1A8, and 1A10 (20 pmol/min/mg protein) at
the high substrate concentration (600 M) (Fig. 3). The findings
indicated that the C-8 phenolic group of daphnetin was more selec-
tively catalyzed by UGTs than the C-7 phenol.
UGT1A6 and UGT1A9, which exhibited the highest activity toward
daphnetin, are expressed in both the liver and intestine (Strassburg et al.,
1998; Basu et al., 2004; Miners et al., 2006). Many phenol-containing
xenobiotics are substrates of UGT1A6 and UGT1A9, and significant
overlap of substrate selectivity occurs (Ebner and Burchell, 1993; Uchai-
pichat et al., 2004). The kinetic studies of daphnetin glucuronidation
by UGT1A9 and UGT1A6 showed that these two isoforms had
similar Vmax/Km values for M-1 formation, although the Vmax/Km
value with UGT1A9 was higher than that of UGT1A6 for M-2
formation, which could be attributed to the relative low Km value
with UGT1A9 (Table 3). In addition, the Km values in recombinant
UGT1A9 and UGT1A6 were lower than those in HLM and HIM,
possibly because of 1) the difference in the single/multiple UGT
nature between cDNA-expressed and microsomal samples, 2) the
relatively low fatty acid content in expression systems, because
long-chain unsaturated fatty acids can act as potent competitive
inhibitors of UGT1A9 (Rowland et al., 2008), and 3) the involve-
ment of other UGTs for the formation of M-1 at high substrate
concentrations (UGT1A3 and UGT1A4 for HLM and UGT1A3,
1A4, 1A7, 1A8, and 1A10 for HIM) (Fig. 2). The comparable
kinetic profiles of UGT1A9 and UGT1A6 were also confirmed by
the evidence from monophasic Eadie-Hofstee plots observed in
HLM and HIM, which suggested that UGT1A9 and UGT1A6 play
major roles in the formation of daphnetin glucuronides in these two
organs, although UGT1A9 showed marginally higher affinity than
that of UGT1A6 (Table 3). Moreover, the findings were also
supported by the results of correlation analysis and the subsequent
inhibition studies: the high correlation between daphnetin glucuro-
nide formation with propofol O-glucuronidation as well as seroto-
nin O-glucuronidation was displayed in Fig. 4, and the comparable
inhibitory effects of phenylbutazone and mefenamic acid on human
liver and intestine microsomes with similar IC50 values can be seen
from Table 2. It should be noted that mefenamic acid is a known
potent inhibitor of UGT1A9 and UGT2B7 in the literature (Tachi-
bana et al., 2005; Gaganis et al., 2007). Because UGT2B7 was not
FIG. 3. Inhibitory effects of phenylbutazone and mefenamic acid on the formation
of daphnetin glucuronidated metabolites (M-1 and M-2) in HLM, RLM, and PLM.
Daphnetin (200 M) was incubated with HLM, RLM, and PLM (0.1 mg of
protein/ml) and either phenylbutazone (50 and 500 M) or mefenamic acid (10 and
100 M) at 37°C for 10 min. Data are expressed as means  S.D. of duplicate
incubations.
TABLE 2
Inhibition of daphnetin glucuronidation in HLM, HIM, and recombinant UGTs
with mefenamic acid and phenylbutazone
Daphnetin was incubated with microsomes (0.1 mg/ml) and UDPGA (5 mM) for 10 min
in the presence of mefenamic acid (1–50 M) or phenylbutazone (10–500 M). The IC50




M-1 M-2 M-1 M-2
M
UGT1A6 50 50 41.1  5.6 40.3  4.2
UGT1A9 8.1  1.6 2.5  0.2 36.4  2.8 39.2  3.2
HLM 10.4  2.2 10.5  2.6 52.3  4.1 59.4  3.4
HIM 8.8  0.9 7.8  2.7 57.2  3.6 61.2  2.4
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found to be involved in daphnetin glucuronidation, mefenamic acid
can seen as a selective inhibitor of UGT1A9 in this study. In vitro
UGT conjugation pathways of daphnetin in human liver and intes-
tine are proposed in Fig. 6. As reported, UGT1A7, UGT1A8, and
UGT1A10 are exclusively expressed in the gastrointestinal tract
(Fisher et al., 2001), and thus these isoforms cannot be involved in
the formation of the 7-O-monoglucuronide daphnetin (M-1) in
HLM.
In the current study, large interindividual variability (57.9% CV
for M-1 and 59.3% for M-2) was observed in the liver samples
from 14 donors, which could be attributed to the effect of age, sex,
enzyme inducers (e.g., drugs, tobacco, and alcohol), and genetic
polymorphism on the enzyme sources from different donors
(Court, 2010). In agreement with our data, the work of Court
(2005) showed that UGT1A9-mediated propofol glucuronidation
(CV 55%) and UGT1A6-mediated serotonin glucuronidation (CV
76%) had high variability within a human liver bank containing 54
individuals. Because of the large interindividual variability in the
hepatic glucuronidation of daphnetin, the different response to the
pharmacokinetic and clinical outcomes within people after admin-
istration of daphnetin can be forecast. Furthermore, interactions
induced by daphnetin with dietary components and other com-
pounds primarily catalyzed by UGT1A9 and UGT1A6 should be
given attention in clinical applications.
In vivo clearance prediction from in vitro enzyme kinetic parame-
ters of the kinetic data for daphnetin glucuronidation in HLM and
HIM was performed, and results showed that the in vivo intrinsic
clearance in liver was markedly larger than that in intestine (344
versus 9.7 ml/min/kg b.wt.), which suggested that the liver might play
a major role in daphnetin metabolic clearance via glucuronidation.
The well stirred model was constrained to predict the hepatic clear-
ance in this study, considering that gut is not a single homogeneous
tissue like liver because intestinal UGTs are mainly expressed in
intestinal mucosa and the UGT activities are also not same in different
FIG. 4. Correlation analysis between the for-
mation rate of metabolite (M-1 or M-2) and
UDP-glucuronosyltransferase isozyme-cata-
lyzed glucuronidation in microsomes from 14
individual human livers. Daphnetin (100 M)
was incubated with microsomes (0.1 mg of
protein/ml) for 10 min. Data represent the
mean of duplicate determinations. For the
formation rate of M-1, the x-axis represents
the activity for propofol glucuronidation (A)
and serotonin glucuronidation (C). For the
formation rate of M-2, the x-axis represents
the activity for propofol glucuronidation (B)
and serotonin glucuronidation (D).
TABLE 3
Kinetic parameters of daphnetin glucuronidation in microsomes obtained from humans, experimental animals (n  5), and recombinant UGT1A9 and UGT1A6
Daphnetin was incubated with microsomes (0.1 mg/ml) and UDPGA (5 mM) for 10 min. The kinetic parameters were calculated with Origin software.
UGT Source
M-1 M-2
Vmax Km Vmax/Km Vmax Km Vmax/Km
nmol/min/mg protein M l/min/mg protein nmol/min/mg protein M l/min/mg protein
HLM 25.3  0.3 122  4.0 219 18.8  0.3 103  4.2 183
RLM 54.9  3.1 165  14 333 19.0  0.5 56.6  5.4 335
PLM 114  18 217  21 526 152  13 175  17 866
HIM 13.5  0.2 199  6.2 65.5 6.9  0.2 161  8.3 42.5
UGT1A9 12.4  0.3 60.5  3.9 207 8.1  0.2 44.3  4.1 183
UGT1A6 15.6  0.3 74.4  4.1 208 7.4  0.3 74.4  8.8 99
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regions of the intestine (Strassburg et al., 1998). The predicted results
showed that daphnetin was a high-clearance molecule in vivo with a
hepatic extraction ratio larger than 0.7 and that most of the orally
administered daphnetin might not reach the systemic circulation be-
cause of the significant first-pass hepatic metabolism. Therefore,
given the high clearance of daphnetin by glucuronidation, how to
retain the plasma concentration of daphnetin to achieve the therapeu-
tic effect remains to be determined. In addition, whether the metab-
olites (M-1 and M-2) can play a role in pharmacological activity needs
to be understood.
Two monoglucuronide metabolites (M-1 and M-2) were detected in
liver microsomes of all species and HIM. However, no diglucuronide
was detected in any of the microsomal samples, which may be
attributable to the steric hindrance of conjugation at one catecholic
hydroxyl group from the conjugation at the other group as reported
previously (Lautala et al., 2000). The metabolic profiles and en-
zyme kinetic parameters can be used to evaluate the variation
among species (Shiratani et al., 2008). The inhibitory patterns are
also very important for selection of animal model(s) suitable to
investigate the pharmacodynamics, toxicology, and pharmacoki-
netics of new chemical entities (Mano et al., 2008). For further
evaluation of daphnetin glucuronidation in HLM, RLM, and PLM,
inhibition assays were conducted. The inhibition studies with phenyl-
butazone and mefenamic acid showed significant species differences
FIG. 5. Enzyme kinetics of daphnetin glucu-
ronidation by HLM (A), HIM (B), UGT1A9
(C), and UGT1A6 (D). Daphnetin was incu-
bated with pooled HLM and HIM (5–600 M,
0.1 mg of protein/ml) or UGT1A9 and
UGT1A6 (5–400 M, 0.1 mg of protein/ml) at
37°C for 10 min. An Eadie-Hofstee plot is
shown as an inset to illustrate monophase
kinetics.
FIG. 6. In vitro UGT conjugation pathways of daphnetin in human
liver and intestine microsomes.
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(Fig. 3), indicating that different UGT isozymes may contribute to the
glucuronidation of daphnetin among these species.
In conclusion, daphnetin is extensively glucuronidated in in vitro
incubation systems in the presence of UDPGA. UGT1A9 and
UGT1A6 are identified as the major isoforms for daphnetin glucu-
ronidation in HLM and HIM. More studies on the biological activities
of these glucuronide metabolites are needed. Our results confirmed
the crucial role of UGT1A9 and UGT1A6 in the glucuronidation of
catechol-containing compounds in humans and further suggested that
daphnetin might serve as a probe substrate for UGT1A6 and UGT1A9
to phenotype the UGTs in liver microsomes from human and animals.
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